7月26日，"2025北京国际胸外科学术大会暨第九届中意胸外科微创学术研讨会"在北京召开。大会以"赋能、致远"为主题，聚焦胸外科领域的最新技术与挑 战，搭建高水平的学术交流平台，共同擘画学科未来发展蓝图。 会议围绕肺癌、食管癌、纵隔肿瘤、胸壁疾病、肺移植等核心疾病，深入探讨微创手术技术革新、围术期综合治疗（特别是靶向治疗、免疫治疗的应用）、 肺移植关键技术与供体评估、快速康复理念、肺癌全程管理以及人工智能在预测术后并发症、辅助诊疗决策等领域的突破性应用。中外专家通过主题演讲、 名家对话等形式，分享了各自领域的最新研究成果和临床实践经验。 通常来讲，IA期首选微创手术根治切除，术后是不需要辅助治疗的，但为什么IA期仍旧有10-15%的患者会出现复发转移？大会上，首都医科大学宣武医院 胸外科主任张毅教授报告了针对术后病理确诊为IA期但合并高风险因素（如病理亚型实体性、微乳头型，气腔播散，脉管瘤栓等的非小细胞肺癌患者）， 其团队进行的回顾性研究发现，对于这部分传统认为"术后无需治疗"的早期患者，若存在特定高风险因素，术后接受药物辅助治疗，能显著降低复发率并延 长患者生存期。这一发现为早期肺癌患者的个体化精准治疗提供 ...

Core Insights - Small cell lung cancer (SCLC) is referred to as the "little devil" in the cancer community, with an increasing incidence in Shandong province, contrasting with the declining trend in Western countries [1][5] - In Shandong, SCLC accounts for 18% to 20% of newly diagnosed lung cancer patients, which is higher than in Western countries, indicating a significant challenge in its prevention and treatment [5][6] Group 1: Incidence and Statistics - China has the highest lung cancer incidence and mortality rates globally, with SCLC patients facing numerous clinical challenges due to their low proportion, high malignancy, and short overall survival [4] - In Shandong, SCLC is particularly prevalent in areas with poor smoking control, contributing to the rising incidence [5] Group 2: Treatment Advances - The treatment landscape for SCLC has evolved from primarily chemotherapy and chemoradiotherapy to an era of immunotherapy, significantly improving survival rates [6] - In the extensive stage, combining immunotherapy with chemotherapy has resulted in over 50% of patients surviving for more than one year, a notable improvement from previous chemotherapy-only survival rates [6] - For limited-stage SCLC patients who respond well to chemoradiotherapy, adding immunotherapy has led to a 60% three-year survival rate [6] Group 3: Risk Factors - The primary risk factor for SCLC is smoking, with most patients being smokers, while a family history of lung cancer also increases risk [6]